Sun Plunges To Quarterly Loss, Outlook Challenging

Sun Pharma, India’s biggest drug firm, slid into the red in the first quarter, hit by a hefty legal payout, regulatory woes and a dramatic drop in US sales, and company founder Dilip Shanghvi said while he expected a “gradual improvement” in performance, the outlook remained challenging.

fishing boat giant wave storm rogue wave
SUN FACES CHALLENGING TIMES AHEAD

Sun Pharmaceutical Industries Ltd., the world’s fifth-largest specialty generic-maker, crashed to a INR4.25bn ($66m) net loss in the first financial quarter as the company forked out $150m to settle a US “pay-for-delay” legal suit and battled increasingly fierce competition in its main US market. It was Sun’s first quarterly loss in over a decade and its weak earnings outlook prompted analysts to slash profit estimates for the current and next financial year.

“Our Q1 performance was not good and not in line with our past performance,” Sun’s billionaire managing director Dilip Shanghvi,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip